Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $72.33.
Several research firms have weighed in on QTTB. Raymond James initiated coverage on Q32 Bio in a research note on Thursday, October 24th. They issued a “strong-buy” rating and a $90.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Q32 Bio in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $95.00 price target on the stock.
Read Our Latest Analysis on Q32 Bio
Institutional Investors Weigh In On Q32 Bio
Q32 Bio Stock Up 0.6 %
Shares of NASDAQ QTTB opened at $48.00 on Thursday. Q32 Bio has a 1 year low of $8.24 and a 1 year high of $53.79. The firm’s 50-day moving average is $45.84 and its 200-day moving average is $34.07. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $578.88 million, a PE ratio of -2.08 and a beta of -0.32.
Q32 Bio (NASDAQ:QTTB – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.42). Equities analysts expect that Q32 Bio will post -12.13 EPS for the current year.
About Q32 Bio
Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
Featured Stories
- Five stocks we like better than Q32 Bio
- 3 Grocery Stocks That Are Proving They Are Still Essential
- What a Trump Win Looks Like for the Market Now and Into 2025
- What to Know About Investing in Penny Stocks
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.